Whitehawk Therapeutics (WHWK) Debt to Equity (2020 - 2021)
Whitehawk Therapeutics (WHWK) reported Debt to Equity of $0.04 for Q4 2021, up 103.83% year-over-year from $0.02 in Q4 2020, and up 15.16% quarter-over-quarter from $0.04 in Q3 2021.
Whitehawk Therapeutics (WHWK) Debt to Equity (2020 - 2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 2 years of Debt to Equity data on file, last reported at $0.04 in Q4 2021.
- Debt to Equity for Q4 2021 came in at $0.04, up 103.83% year-over-year; the trailing twelve-month figure through Dec 2021 was $0.04 (up 103.83% YoY), and the FY2021 annual result was $0.04, up 103.83% from the prior year.
- Debt to Equity improved to $0.04 in Q4 2021 per WHWK's latest filing, from $0.04 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.04 in Q4 2021 and troughed at -$1.15 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.04 |
| Dec 31, 2020 | -1.15 |